Diethylstilbestrol Diphosphate

Summary

Diethylstilbestrol Diphosphate (CHEMBL1200598) is an approved small molecule (ATC L02AA04); indicated across 1 condition including neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L02AA04
• Indications: 1 condition
• Chemistry: 428.3 Da · C18H22O8P2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200598
Name	Diethylstilbestrol Diphosphate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3032325
ATC	L02AA04
Molecular formula	C18H22O8P2
Molecular weight	428.3
InChIKey	NLORYLAYLIXTID-ISLYRVAYSA-N

SMILES: CC/C(=C(/CC)\C1=CC=C(C=C1)OP(=O)(O)O)/C2=CC=C(C=C2)OP(=O)(O)O

IUPAC name: [4-[(E)-4-(4-phosphonooxyphenyl)hex-3-en-3-yl]phenyl] dihydrogen phosphate

Also known as: Diethylstilbestrol diphosphate, Fosfestrol, Stilphostrol, SID50125929, DIETHYLSTILBESTROL DIPHOSPHATE, FOSFESTROL, SID144206347

Patent coverage: 2,086 distinct patent families (7,909 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: RecQ-like DNA helicase BLM.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).